Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 20.
doi: 10.1007/s12265-024-10489-8. Online ahead of print.

Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis

Hongchao Zheng #  1 , Yuntao Zheng #  2 , Wei Huang  2 , Lingling Jiang  1 , Siyu Liu  1 , Peizhi Miao  1 , Ning Zhu  1 , Richard Y Cao  3
Affiliations

Exploration of the Potential Biomarker FNDC5 for Discriminating Heart Failure in Patients with Coronary Atherosclerosis

Hongchao Zheng et al. J Cardiovasc Transl Res. .

Abstract

Coronary atherosclerosis leading to ischemic artery disease is one of the etiological factors to develop heart failure (HF). This study aimed to investigate potential biomarkers for discriminating HF in atherosclerotic patients. This study included 40 consecutive atherosclerotic patients who underwent angiography. Concentrations of B-type natriuretic peptide (BNP), fibronectin type III domain containing 5 (FNDC5), and Phosphodiesterase 9A (PDE9A) were measured in 20 atherosclerotic patients with HF symptoms/signs and 20 without HF symptoms/signs. Circulating BNP levels were elevated, while FNDC5 levels were reduced in atherosclerotic patients with HF symptoms/signs compared to those without HF symptoms/signs. Pearson correlation analysis showed a significant correlation between FNDC5 and BNP. Receiver Operating Characteristics analysis indicated that both FNDC5 and BNP were able to discriminate HF in atherosclerotic patients. Our findings suggest that FNDC5, along with BNP, has independent value as a biomarker for discriminating HF in patients with coronary atherosclerosis.

Keywords: BNP; Biomarker; Coronary atherosclerosis; FNDC5; Heart failure.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. GBD 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7 . - DOI
    1. Fernandes VRS, Cheng S, Lima JAC. Atherosclerosis imaging and heart failure. Heart Fail Rev. 2006;11:279–88. https://doi.org/10.1007/s10741-006-0229-7 . - DOI - PubMed
    1. Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158:2119–29. https://doi.org/10.1016/j.chest.2020.05.552 . - DOI - PubMed - PMC
    1. Gevaert AB, Kataria R, Zannad F, et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108:1342–50. https://doi.org/10.1136/heartjnl-2021-319605 . - DOI - PubMed
    1. Adamson PD, Hunter A, Madsen DM, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018;11:e004227. https://doi.org/10.1161/circoutcomes.117.004227 . - DOI - PubMed - PMC

LinkOut - more resources